[
    [
        {
            "time": "2018-04-10",
            "original_text": "SEC's Clayton says agency right not to rule on Johnson & Johnson shareholder proposal concerning mandatory arbitration",
            "features": {
                "keywords": [
                    "SEC",
                    "Clayton",
                    "Johnson & Johnson",
                    "shareholder proposal",
                    "mandatory arbitration"
                ],
                "sentiment_score": -0.2,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "FDA Panel Reviews Johnson & Johnson's Treatment-Resistant Depression Candidate: What To Expect",
            "features": {
                "keywords": [
                    "FDA",
                    "Panel",
                    "Johnson & Johnson",
                    "Treatment-Resistant Depression",
                    "Candidate"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "What Are Analysts Saying About Johnson & Johnsonâ€™s (NYSE:JNJ) Growth?",
            "features": {
                "keywords": [
                    "Analysts",
                    "Johnson & Johnson",
                    "Growth"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 3,
                "Duration": 2,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        }
    ]
]